What We Do

Turning Ideas Into Outcomes

By your side, bringing your vision to life.

We are not just advisors, but partners deeply invested in your success.

Our Services

From product development to advocacy, we deliver practical support at the intersection of innovation and health outcomes.

Medical Product Development

Focusing on lived experience, we establish programs that measure meaningful outcomes to define the value of your healthcare solutions.

• Evidence & endpoint strategies
• Study design
• Clinical Outcome Assessments
• Product potential
• Regulatory strategy

Patient Advocacy & Experience

Blue Persimmon advisors develop advocacy strategies and consortia collaborations to amplify your influence and drive positive change.

• Lived experience research
• Public-private partnerships
• Research priorities
• Patient-focused drug development

Health Outcomes

We develop the evidence needed to improve health outcomes and inform system-level decisions in healthcare and medical product development.

• Real-world evidence
• Qualitative studies
• Health economics
• Health services research
• Outcomes research

Strategic Guidance

Blue Persimmon advisors guide initiatives and organization leaders to ensure program efficiency, precision, and impact.

• Portfolio assessment
• Resourcing strategy
• Program prioritization
• Long-term planning
• Outsourcing approach

Evidence Submissions

We support submissions to health authorities and real-world audiences to ensure your innovations gain the recognition and support they deserve.

• Stakeholder research
• Advisory boards
• Submission strategy
• Dossier development
• Health authority interactions
• Scientific communications

Fractional Service Provider

Blue Persimmon leaders step in part-time to stand up functions, guide priority work, and keep momentum while you hire or scale.

• Interim heads & program leads
• Vendor selection & management
• Budgeting & resourcing
• Operations & strategy
• Transition plans & onboarding

Our Process

Collaborative, Strategic, Iterative, Impactful

Our Process

Collaborative, Strategic, Iterative, Impactful.

Targeted & agile approaches

Evidence-based iteration

Outcome-focused analysis

Transformational innovation

From Idea to Impact

We partner with vision-centered teams to translate research, connect stakeholders, and shape strategy for real-world impact.

A few of our recent projects are highlighted here!

National and State Societal Costs of Schizophrenia in the US in 2024

JAMA Psychiatry
January 28, 2026

Krasa HB, Baumgardner JR, Brewer IP, Chou JW, Flottemesch T, Markowitz JT, Williams C, Nagendra A.

Quantifying the Societal Impacts of Schizophrenia: A Survey of Caregivers

Psychiatric Research and Clinical Practice
Sep 22, 2025

Krasa HB, Birch K, Eskew F, Frangiosa T, Paslgrove A, Maravic MC.

Our Publications & Presentations

Explore how our team has helped move bold ideas forward. Scroll through our list of publications and presentations below.

National and State Societal Costs of Schizophrenia in the US in 2024

JAMA Psychiatry | January 28, 2026 | Read Here

Impact of Medicaid IMD exception on serious mental illness outcomes

American Journal of Managed Care | December 2025 | Read Here

The Impact of Copay Accumulators and Maximizers on Treatment Patterns, Adherence, and Costs Among Patients with Major Depressive and Bipolar Disorders Treated with Branded Therapies

Journal of Market Access & Health Policy | November 7, 2025 | Read Here

Quantifying the societal impacts of schizophrenia: A survey of caregivers

Psychiatric Research and Clinical Practice | September 22, 2025 | Read Here

Open access to antipsychotics in state Medicaid programs: effect on healthcare resource utilization and costs among patients with serious mental illness

JHEOR | June 17, 2025 | Read Here

Quantifying the independent impact of social determinants of health and posttraumatic stress disorder on resource utilization and health outcomes in civilians: A real-world evidence analysis

Psych Services | June 2025 | Read here

RESISTE Scholars: Empowering Future Hispanic-Serving Institution Researchers through Collaborative Mentorship

Journal of Underrepresented & Minority Progress | January 2025 | Read Here

Self-stigmatization and treatment preferences: Measuring the impact of treatment labels on choices for depression medications

PLoS ONE | September 3, 2024 | Read Here

Evaluation of digital mental health technologies in the United States: Systematic literature review and framework synthesis

JMIR Ment Health | August 30, 2024 | Read Here

Insights into insurance coverage for digital therapeutics: a qualitative descriptive study from a US payer perspective

JMCP | March 31, 2024 | Read Here

Care partner evaluation of the behaviors in the Cohen-Mansfield Agitation Inventory

Frontiers in Dementia | March 8, 2024 | Read Here

Mixed-methods research to support the use of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library

Journal of Patient-Reported Outcomes | January 22, 2024 | Read Here

Changes in antipsychotic medication use among Medicare patients in a nursing home, 2010 – 2015

American Health & Drug Benefits | 2023 | Read Here

Beyond Clinical Outcomes: Case control study of the role of race in disruptive life events for people with serious mental illness

General Hospital Psychiatry | November 2023 | Read Here

Understanding patients’ experiences with borderline personality disorder: Qualitative interviews

Neuropsychiatric Disease and Treatment | October 9, 2023 | Read Here

Patient-Reported Outcomes Measures, Polycystic Kidney Disease Burden, and Outcomes in Autosomal Dominant Polycystic Kidney Disease

Kidney Medicine | November 27, 2023 | Read Here

Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis

BMC Nephrology | June 22, 2023 | Read Here

Beyond Clinical Outcomes: Using TransUnion public records data to assess disruptive life events for individuals diagnosed with schizophrenia or bipolar I disorder

JAMA Psychiatry | May 10, 2023 | Read Here

Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's

Neurology and Therapy | April 12, 2023 | Read Here

Treatment patterns and adverse events among Medicare beneficiaries using antipsychotic medications for FDA-approved indications before and after transitioning from the home to a nursing home

Current Medical Research & Opinion | April 2023 | Read Here

Life engagement improvement following initiation of brexpiprazole treatment in patients with MDD: A naturalistic, retrospective real-world study

Clinicoecon Outcomes Res. | March 18, 2023 | Read Here

A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients with Autosomal Dominant Polycystic Kidney Disease

Kidney International Reports | February 13, 2023 | Read Here

Assessing What Matters to People Affected by Alzheimer’s Disease: A Quantitative Analysis

Neurology and Therapy | February 10, 2023 | Read Here

Caregiver Burden of Autosomal Dominant Polycystic Kidney Disease: A Qualitative Study

Kidney Medicine | February 2023 | Read Here

Psychiatric healthcare resource utilization following initiation of aripiprazole once-monthly: A retrospective real-world study

Current Medical Research and Opinion | February 2023 | Read Here

Development of a Patient-Reported Outcomes Tool to Assess Pain and Discomfort in Autosomal Dominant Polycystic Kidney Disease

Clinical Journal of the American Society of Nephrology | January 17, 2023 | Read Here

The effects of early initiation of aripiprazole once-monthly 400 mg on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data

Journal of Medical Economics | January 2023 | Read Here

Readmissions, costs, and duration to subsequent outpatient visit after hospital discharge among Medicaid beneficiaries utilizing oral versus long-acting injectable antipsychotics in bipolar disorder or schizophrenia

Current Medical Research and Opinion | September 2022 | Read Here

“I Can’t Take off My Shirt or Do My Own Hair”—A Qualitative Investigation of the Symptoms and Impact Experience of Children and Adolescents with Fibrodysplasia Ossificans Progressiva (FOP)

Advances in therapy | April 16, 2022 | Read Here

Mental health care providers’ perspectives toward adopting a novel technology to improve medication adherence

Psychiatric Research and Clinical Practice | April 2022 | Read Here

Developing a Conceptual Disease Model of Patient Experiences and Identifying Patient-Reported Clinical Outcome Assessments for Use in Trials of Treatments for Focal Onset Seizures

Neuropsychiatric Disease and Treatment | March 22, 2022 | Read Here

Pooled Data Analysis of the Long-Term Treatment Effects of Tolvaptan in ADPKD

Kidney International Reports | February 19, 2022 | Read Here

Antipsychotic-related stigma and the impact on treatment choices: A systematic review and framework synthesis

Patient Prefer Adherence | February 2022 | Read Here

Polycystic Kidney Disease–Related Disease Burden in Adolescents with Autosomal Dominant Polycystic Kidney Disease: An International Qualitative Study

Kidney Medicine | January 21, 2022 | Read Here

An Integrated pharmacokinetic–pharmacodynamic–pharmacoeconomic modeling method to evaluate treatments for adults with schizophrenia

PharmacoEconomics | January 2022 | Read Here

Mental illness disclosure in the workplace: An opportunity for improvement

Am Health Drug Benefits | December 2021 | Read Here

Societal Costs of Schizophrenia in 2020

Schizophrenia & Psychosis Action Alliance Report | November 21, 2021 | Read here

Impact of treatment-related adherence discussion on healthcare resource use and costs among patients with severe mental illness

Current Medical Research Opinion | October 2021 | Read Here

Treatment compliance communications between patients with severe mental illness and treating healthcare providers: A retrospective study of documentation using healthcare reimbursement claims and medical chart abstraction

Pragmatic and Observational Research | June 15, 2021 | Read Here

Depression screening in pediatric type 1 diabetes: descriptive assessment of parental reactions to elevated depressive symptom scores

Pediatric Diabetes | October 8, 2020 | Read Here

Patient-reported burden of dry eye disease in the United States: results of an online cross-sectional survey

American Journal of Opthalmology | August 2020 | Read Here

Assessing what matters most to patients with or at risk for Alzheimer’s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes

Alzheimer’s Research & Therapy | July 30, 2020 | Read Here

Review of Clinical Outcome Assessments in Pediatric Attention-Deficit/Hyperactivity Disorder

Neuropsychiatric Disease and Treatment | May 28, 2020 | Read Here

Assessing readiness for independent self-care in adolescents with type 1 diabetes: Introducing the RISQ

Diabetes research and clinical practice | April 2020 | Read Here

A retrospective cohort review of opioid prescribing and patient-reported consumption patterns following upper extremity surgery

Current Orthopaedic Practice | March 2020 | Read Here

Healthcare cost in patients with schizophrenia treated with brexpiprazole vs. other oral atypical antipsychotic therapy

Clinical Therapeutics | January 2020 | Read Here

A claims-based algorithm to reduce relapse and cost in schizophrenia

American Journal of Managed Care | December 1, 2019 | Read Here

A Comparison of PROMIS Global Health-Mental and Legacy Orthopedic Outcome Measures for Evaluating Preoperative Mental Health Status

Journal of Orthopaedics | November 27, 2019 | Read Here

Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review

Journal of Medical Economics | June 22, 2019 | Read Here

Chronic hyponatremia and association with osteoporosis among a large racially/ethnically diverse population

Osteoporosis International | April 30, 2019 | Read Here

Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review

Pharmacoeconomics | April 9, 2019 | Read Here

Evaluation of patient support program and adherence to long-acting injectable aripiprazole for patients utilizing injection local care centers

Current Medical Research and Opinion | November 5, 2018 | Read Here

Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument

American Journal of Kidney Diseases | February 2018 | Read Here

Relapse risk assessment for schizophrenia patients (RASP): A new self-report screening tool

Clinical Schizophrenia | January 2018 | Read Here

Examination of psychosocial and physiological risk for bulimic symptoms in youth with type 1 diabetes transitioning to an insulin pump: a pilot study

Journal of Pediatric Psychology | January 1, 2018 | Read Here

Prevalence of autosomal dominant polycystic kidney disease in the European Union

Nephrology Dialysis Transplantation | August 1, 2017 | Read Here

Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease

Nephrology Dialysis Transplantation | June 1, 2017 | Read Here

Severity of memory impairment in the elderly: Association with health care resource use and functional limitations in the United States

Alzheimer’s & Dementia | April 20, 2017 | Read Here

Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial

Nephrology Dialysis Transplantation | November 2016 | Read Here

Investigation of the Neurocognitive Impact of Sodium Improvement in Geriatric Hyponatremia: Efficacy and Safety of Tolvaptan (INSIGHT) Investigators. Tolvaptan and Neurocognitive Function in Mild to Moderate Chronic Hyponatremia: A Randomized Trial (INSIGHT)

American Journal of Kidney Diseases | June 2016 | Read Here

Depressive symptoms, emotion dysregulation, and bulimic symptoms in youth with type 1 diabetes: varying interactions at diagnosis and during transition to insulin pump therapy

Journal of Diabetes Science and Technology | May 2, 2016 | Read Here

Prevalence of disturbed eating behavior in children and adolescents with type 1 diabetes: assessment and comparison to healthy peers – results of a multicenter questionnaire-based study

Psychotherapie, Psychosomatik, medizinische Psychologie | March 2016 | Read Here

Lack of tolerable treatment options for patients with schizophrenia

Neuropsychiatric Disease & Treatment | December 16, 2015 | Read Here

Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database

Drug Safety | November 2015 | Read Here

Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC)

American Journal of Kidney Diseases | October 2015 | Read Here

Short-term Effects of Tolvaptan in Individuals with Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function

American Journal of Kidney Diseases | June 2015 | Read Here

Evaluating the impacts of the FDA’s guidance for patient-reported outcomes (PROs) measures on clinical trial-based approved drug product labeling claims, 2006–2014

Clinical Research and Regulatory Affairs | March 12, 2015 | Read Here

Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data

Clinicoeconomics and Outcomes Research | February 20, 2015 | Read Here

Psychometric properties of the German version of the Diabetes Eating Problem Survey-Revised (DEPS-R): additional benefit of disease-specific screening in adolescents with type 1 diabetes

Diabetic Medicine | December 2015 | Read Here

Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease

Kidney International | December 2013 | Read Here

Technology to Optimize Pediatric Diabetes Management and Outcomes

Current Diabetes Reports | September 18, 2013 | Read Here

The development of a patient-reported outcome measure for assessing nighttime symptoms of chronic obstructive pulmonary disease

Health and Quality of Life Outcomes | June 25, 2013 | Read Here

Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan

Journal of Cardiac Failure | June 2013 | Read Here

Disordered eating behaviors in youth with type 1 diabetes: prospective pilot assessment following initiation of insulin pump therapy

Diabetes Technology & Therapeutics | May 1, 2013 | Read Here

Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia

Psychiatry Research | December 30, 2012 | Read Here

Short-term effects of tolvaptan on renal function and volume in patients with Autosomal Dominant Polycystic Kidney Disease

Kidney International | August 1, 2011 | Read Here

Utilities and disutilities for attributes of injectable treatments for type 2 diabetes

The European Journal of Health Economics | June 12, 2011 | Read Here

Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3:4 Study

American Journal of Kidney Diseases | May 2011 | Read Here

Validation of an abbreviated adherence measure for young people with type 1 diabetes

Diabetic Medicine | April 19, 2011 | Read Here

Effect of Serum Sodium Concentration and Tolvaptan Use on Length of Stay in Patients Hospitalized with Heart Failure

American Journal of Health-System Pharmacy | February 15, 2011 | Read Here

Brief screening tool for disordered eating in diabetes: internal consistency and external validity in a contemporary sample of pediatric patients with type 1 diabetes

Diabetes Care | 2010 | Read Here

Self-reported history of overweight and its relationship to disordered eating in adolescent girls with type 1 diabetes

Diabetic Medicine | November 4, 2009 | Read Here

Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators

European Heart Journal | September 2009 | Read Here

Development and content validity of a gastroparesis cardinal symptom index daily diary

Alimentary Pharmacology & Therapeutics | September 15, 2009 | Read Here

Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program

Journal of the American College of Cardiology | November 11, 2008 | Read Here

Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial

Journal of the American College of Cardiology | November 4, 2008 | Read Here

Perceived deprivation, restrained eating, and susceptibility to weight gain

Appetite | November 2008 | Read Here

Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction

Journal of the American Medical Association | June 11, 2008 | Read Here

Pregnancy and Obesity: A Review and Agenda for Future Research

Journal of Women’s Health | August 15, 2006 | Read Here

Multiple types of dieting prospectively predict weight gain during the freshman year of college

Appetite | July 2006 | Read Here

Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study

Arthritis & Rheumatism | December 2004 | Read Here

Have a challenge? We love those.

Tell Us More